Partnering | Novartis

With global biomedical innovation moving at an unparalleled pace, partnering fuels scientific progress and patient care. At Novartis, we're collaborating with innovators to address some of society's most challenging healthcare issues.

30+

strategic deals over the last 2+ years

~120

countries where Novartis products are sold

9.3 bn

Core R&D spend in 2024 (USD)*

*Core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Novartis Fourth Quarter and Full Year 2024 Condensed Financial Report.

Partnering focus areas

We are an innovative medicines focused company working on four therapeutic areas and five technology platforms.

Therapeutic areas

Partnering - Cardiovascular, renal & metabolic

Our efforts include use of early interventions and development of pioneering treatments, from prevention to management, as well as the creation of innovative access models. Our goal is to reduce and ultimately stop premature death and disability from cardiovascular disease.

Learn more

Partnering - Immunology

We focus on discovering and developing transformative therapies, including small molecules and biotherapeutics that target the root cause of these diseases by modulating the immune system to restore health.

Learn more

Partnering - Neuroscience

We look to deliver life-changing solutions and treatments that address the underlying cause of neurodegenerative, neurodevelopmental and neuromuscular diseases to dramatically improve the lives of patients.

Learn more

Partnering - Oncology

We are committed to developing new therapeutic approaches that offer the potential of changing future treatment paradigms and patient journeys therapies for a range of common and rare cancers.

Learn more

Technology platforms

Partnering - Chemistry

We aim to discover and develop breakthrough molecules by boldly enabling unprecedented biological space with suitably crafted compounds across diverse chemical modalities.

Learn more

Partnering - Biotherapeutics

We strive to leverage cutting-edge science and technology to create novel biotherapeutics that deliver transformative impact in healthcare, and we are dedicated to advancing the production of high-quality biologics, with the goal of ultimately bringing safe and effective treatments to patients in need.

Learn more

Partnering - xRNA

At Novartis, we are pursuing innovative and ground-breaking therapies designed to target RNA and silence disease-causing genes inside cells.

Learn more

Partnering - Radioligand therapy

We are committed to reimagining cancer care by pushing the boundaries of innovation with bold science, like targeted radioligand therapy (RLT) for patients with advanced cancers.

Learn more

Partnering - Cell and gene therapy

We are pioneers on the cell and gene therapy frontier, working at the edge of possibility with emerging tools to bring entirely new types of treatments to patients with devastating diseases, including genetic disorders and certain deadly cancers.

Learn more

Other areas of interest

In addition to our areas of focus, Novartis also looks to partner in other disease, research and technology areas.

Learn more

Partnering is at the core of our business

We collaborate to address some of society's most challenging healthcare issues and have a unified partnering strategy fueled by clarity, agility, accountability, and efficiency.

See our approach

Get in touch

Our Corporate & Business Development team would like to hear from you.

Large crowd in an auditorium on Basel campus

Where to meet us

See which events Novartis will be attending.

Learn more

Discover more

Leadership team

Get to know the Corporate & Business Development team

Our approach

Discover how we collaborate to address some of society s most challenging healthcare issues